These enrichment results are not only consistent with the known molecular pathological characteristics of OI bone, including molecular signatures of increased bone turnover and reduced bone maturation, but also reveal that a TGF-β downstream event, SMAD phosphorylation, was the most affected target in OI type III bone. The gene discussed is TGFB1; the disease is osteogenesis imperfecta.